Welcome to LookChem.com Sign In|Join Free

CAS

  • or
2-methyl-3-phenyloct-2-en-4-one is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1092694-44-4

Post Buying Request

1092694-44-4 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1092694-44-4 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1092694-44-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,9,2,6,9 and 4 respectively; the second part has 2 digits, 4 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1092694-44:
(9*1)+(8*0)+(7*9)+(6*2)+(5*6)+(4*9)+(3*4)+(2*4)+(1*4)=174
174 % 10 = 4
So 1092694-44-4 is a valid CAS Registry Number.

1092694-44-4Relevant articles and documents

Two distinct classes of novel pyrazolinecarboxamides as potent cannabinoid CB1 receptor agonists

Lange, Jos H.M.,Attali, Amos,Van Der Neut, Martina A.W.,Wals, Henri C.,Mulder, Arie,Zilaout, Hicham,Duursma, Ate,Van Aken, Hans H.M.,Van Vliet, Bernard J.

experimental part, p. 4992 - 4998 (2010/10/05)

The synthesis and SAR of 3-alkyl-4-aryl-4,5-dihydropyrazole-1-carboxamides 1-23 and 1-alkyl-5-aryl-4,5-dihydropyrazole-3-carboxamides 24-27 as two novel cannabinoid CB1 receptor agonist classes were described. The target compounds elicited high

4,5 Dihydro-(1H)-Pyrazole Derivatives as Cannabinoid CB1 Receptor Modulators

-

Page/Page column 10, (2009/01/24)

The invention is directed to 4,5-dihydro-(1H)-pyrazole (pyrazoline) derivatives as cannabinoid CB1 receptor modulators, to pharmaceutical compositions comprising these compounds, to methods for their syntheses, to methods for preparing novel intermediates useful for their syntheses, and to methods for preparing compositions. The invention also relates to the uses of compounds and compositions administered to patients to achieve a therapeutic effect in multiple sclerosis, traumatic brain injury, pain including chronic pain, neuropathic pain, acute pain and inflammatory pain, osteoporosis, appetite disorders, epilepsy, Alzheimer's disease, Tourette's syndrome, cerebral ischaemia, emesis, nausea, and gastrointestinal disorders. Compounds of the present disclosure are directed to formula (I): wherein the substituents have the definitions given in the specification.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1092694-44-4